Cornhill J, Rowley-Jones D
Eur J Rheumatol Inflamm. 1984;7(3):114-21.
One hundred and thirty-one patients with osteoarthritis of the knee or hip entered a comparative trial of sustained release (SR) ibuprofen ('Fenbid') and piroxicam ('Feldene'). Paracetamol was provided as 'escape' medication. During the 3 week treatment period the patients assessed pain and stiffness in either the knee or hip as well as general joint pain and stiffness and duration of morning stiffness, overall wellbeing, sleep disturbance and paracetamol consumption. Physicians assessed response to joint manipulation and the function of the joint subjectively. The results were statistically compared with those from a run-in period during which only paracetamol was given. Over the trial period significant improvement was noted in all of the parameters with both treatments. SR ibuprofen was significantly better than piroxicam at reducing morning stiffness. In addition fewer patients taking ibuprofen experienced upper gastrointestinal symptoms, 4% compared to 20% taking piroxicam.
131名膝关节炎或髋关节炎患者参与了一项缓释布洛芬(“芬必得”)和吡罗昔康(“ Feldene”)的对比试验。对乙酰氨基酚作为“备用”药物提供。在为期3周的治疗期间,患者评估了膝盖或髋部的疼痛和僵硬程度,以及全身关节疼痛和僵硬程度、晨僵持续时间、整体健康状况、睡眠障碍和对乙酰氨基酚的服用量。医生主观评估了关节手法治疗的反应和关节功能。将结果与仅服用对乙酰氨基酚的导入期结果进行统计学比较。在试验期间,两种治疗方法在所有参数上均有显著改善。缓释布洛芬在减轻晨僵方面明显优于吡罗昔康。此外,服用布洛芬的患者出现上消化道症状的较少,分别为4%和20%。